- Home
- KUKE vs BLRX Comparison
KUKE vs BLRX Comparison
Compare KUKE & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- BLRX
- Stock Information
- Founded
- KUKE 2002
- BLRX 2003
- Country
- KUKE China
- BLRX Israel
- Employees
- KUKE N/A
- BLRX N/A
- Industry
- KUKE Other Consumer Services
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- KUKE Real Estate
- BLRX Health Care
- Exchange
- KUKE Nasdaq
- BLRX Nasdaq
- Market Cap
- KUKE 21.2M
- BLRX 17.3M
- IPO Year
- KUKE 2021
- BLRX 2011
- Fundamental
- Price
- KUKE $0.48
- BLRX $0.10
- Analyst Decision
- KUKE
- BLRX Strong Buy
- Analyst Count
- KUKE 0
- BLRX 2
- Target Price
- KUKE N/A
- BLRX $5.50
- AVG Volume (30 Days)
- KUKE 799.4K
- BLRX 18.8M
- Earning Date
- KUKE 01-31-2025
- BLRX 11-25-2024
- Dividend Yield
- KUKE N/A
- BLRX N/A
- EPS Growth
- KUKE N/A
- BLRX N/A
- EPS
- KUKE N/A
- BLRX N/A
- Revenue
- KUKE $14,784,158.00
- BLRX $21,991,000.00
- Revenue This Year
- KUKE N/A
- BLRX N/A
- Revenue Next Year
- KUKE N/A
- BLRX N/A
- P/E Ratio
- KUKE N/A
- BLRX N/A
- Revenue Growth
- KUKE 10.48
- BLRX N/A
- 52 Week Low
- KUKE $0.23
- BLRX $0.08
- 52 Week High
- KUKE $4.07
- BLRX $1.44
- Technical
- Relative Strength Index (RSI)
- KUKE 53.14
- BLRX 28.83
- Support Level
- KUKE $0.39
- BLRX $0.23
- Resistance Level
- KUKE $0.50
- BLRX $0.14
- Average True Range (ATR)
- KUKE 0.10
- BLRX 0.03
- MACD
- KUKE 0.00
- BLRX -0.00
- Stochastic Oscillator
- KUKE 27.29
- BLRX 6.93
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.